Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million

Core Insights - Bain Capital Life Sciences Investors, LLC has acquired a significant stake in HeartFlow, Inc., purchasing 12,448,158 shares valued at approximately $419.00 million, making it the largest holding in the fund's portfolio [2][3][4] Company Overview - HeartFlow, Inc. has a market capitalization of $2.38 billion and reported revenue of $157.75 million with a net income of -$113.33 million for the trailing twelve months [5] - As of November 14, 2025, HeartFlow's stock price was $27.98 [5] Investment Details - The new position in HeartFlow represents 27.81% of Bain Capital Life Sciences Investors, LLC's reportable assets under management [4][7] - This acquisition accounts for approximately 17% of HeartFlow's overall market capitalization, indicating a substantial investment relative to the company's size [12] Company Operations - HeartFlow specializes in non-invasive diagnostics for coronary artery disease, utilizing AI and computational fluid dynamics to create personalized 3D heart models [9][10] - The company primarily generates revenue from healthcare providers and institutions that utilize its proprietary heart modeling technology [9]